Article in Japanese
A case of EBV-associated hemophagocytic lymphohistiocytosis with proliferation of virus-infected B cells on relapse
Hitomi KITANO1), Yosuke FUJII1), Nobuyuki NOSAKA1), Masato YASHIRO1), Akira SHIMADA1), Hirokazu TSUKAHARA1)
This study presented a 2-year-old girl with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH); i.e. EBV infecting her CD8 positive T-cells on disease onset, and being detected preferentially in her B-cells on relapse. She was admitted to this hospital with fever and pancytopenia, and received a diagnosis of EBV-HLH. The EBV genome copy number was monitored in the infected cells by real-time PCR in order to assess disease activity and response to therapy. The EBV genome was detected initially in the T cells. Treatment was started based on the hemophagocytic lymphohistiocytosis (HLH) -2004 protocol during which EBV genome copies became undetectable temporarily, but 1.14×105 copies/ml of the EBV genome were detected at the end of treatment. The EBV genome was detected preferentially in B cells at re-examination. EBV-HLH relapse usually requires hematopoietic stem cell transplantation; however, rituximab is thought to be effective for EBV infection in B cells. After rituximab treatment, EBV genome copies became undetectable persistently. Monitoring the EBV genome copy number and infected cells may be useful in treatment decisions for EBV-HLH.
1) Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
|February 6, 2017
|May 8, 2017